Abstract
The paper provides a brief summary of current preclinical and clinical evidences of dopaminergic system involvement in OCD pathophysiology. We also provide an overview of effectiveness and long-term safety of dopaminergic agents in the treatment of resistant OCD.
Keywords: OCD, resistant-OCD, antipsychotics augmentation, dopamine agents, ondansetron, endogenous, placebo-controlled, quetiapine, olanzapine, aripiprazole, Haloperidol, risperidone augmentation, Sydenham's chorea, amphetamine, cocaine
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Frontiers in Clinical Drug Research-Dementia
COVID-19: Causes, Transmission, Diagnosis, and Treatment
Skeletal Muscle Health in Metabolic Diseases
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Thyroid and Brain: Understanding the Actions of Thyroid Hormones in Brain Development and Function
Cultural Adaptation of Evidence-Based Psychotherapies for Common Mental Health Disorders in Pakistan
Common Lip Diseases: A Clinical Guide
Interventional Pain Surgery
Endoscopy and Fetoscopy Techniques for the Brain and Neuroaxis
16